Point72 Hong Kong LTD Chemo Centryx, Inc. Transaction History

Point72 Hong Kong LTD

$1.35 Billion
Q3 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $33,899 - $60,714	-2,207 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $21,042 - $37,046	-947 Reduced 30.03%	2,207 $55,000
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $57,970 - $127,737	3,154 New	3,154 $115,000
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $133,197 - $183,686	-2,819 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $130,660 - $173,904	2,819 New	2,819 $154,000
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $1,041 - $1,442	-161 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$8.31 - $14.85 $5,210 - $9,310	-627 Reduced 79.57%	161 $1,000
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $7,887 - $10,945	788 New	788 $11,000
Q3 2018 Nov 14, 2018	SELL	$10.49 - $13.72 $975 - $1,275	-93 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$10.62 - $13.98 $987 - $1,300	93 New	93 $1,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.